Over 95% of pregnant women choose some form of prenatal screening, which may ultimately lead to a prenatal diagnosis procedure being performed. Most women will consider serum-based screening tests for aneuploidy, of which Down syndrome (trisomy 21) is by far the most common disorder affecting approximately 1 : 800 pregnancies. Risk can be assessed by combining several factors, including (a) elevated or depressed serum levels of several biomarker proteins including b-hCG, a-fetoprotein, PAPP-A and inhibin A, (b) maternal age and (c) increased nuchal translucency. Based on the risk women can be offered an invasive test to sample fetal material -either by chorionic villus sampling (CVS) or amniocentesis to obtain fetal cells. CVS and amniocentesis impart a small but significant procedure-related risk of spontaneous fetal loss and, of course, of added discomfort and stress to the mother. Noninvasive testing, using a maternal blood sample, has long been the goal to achieve well tolerated prenatal diagnosis. For many decades, it was anticipated that fetal cells, which are known to traffic between fetus and mother, were the best candidates for the source of fetal material in maternal blood. Recent advances in microfluidics and cell separation technology may yet realize this, but in 1997, work performed by Lo et al.
[1] at Oxford University was set to transform the field of noninvasive prenatal diagnosis (NIPD). His pioneering work revealed the presence of free fetal nucleic acids in maternal plasma and serum -the implications of this finding were immediately obvious and have subsequently led to the routine application of NIPD in the clinic. This mini review summarizes the current status of NIPD using free fetal nucleic Purpose of review Free fetal nucleic acids, found in the plasma of every pregnant woman, have made a substantial impact on prenatal diagnosis. The past decade has seen the introduction of routine noninvasive prenatal diagnosis (NIPD) using DNA extracted from maternal plasma for a number of clinical complications of pregnancy, notably feto-maternal blood group incompatibility, fetal sexing and exclusion/detection of single-gene disorders. It appears that mass-scale analysis of all RhD-negative pregnant women will be adopted to conserve stocks of prophylactic anti-D and avoid the administration of a blood product unnecessarily. For the majority of prenatal diagnostic procedures, the assessment of trisomy, particularly trisomy 21, is the highest priority. Because RHD genotyping, fetal sexing and analysis of single-gene disorders all depend on the detection of paternally inherited alleles, they were relatively simple to adapt on the basis of PCR analysis of DNA obtained from maternal plasma. However, for assessment of chromosome copy number, this is not so straightforward.
Recent findings
The assessment of polymorphisms among placentally expressed mRNAs found in maternal plasma has enabled the detection of trisomy 21 fetuses using a combination of reverse transcriptase PCR and mass spectrometry to define allelic ratios of maternally and paternally inherited single nucleotide polymorphisms. Interesting recent developments also include the finding that direct sequence analysis of maternal plasma extracted DNA using 'next-generation' DNA sequencers can differentiate between normal and trisomy fetuses. Summary NIPD using nucleic acids obtained from maternal plasma and serum is now a clinical reality, particularly in the management of hemolytic disease of the fetus and newborn. Recent advances signal that NIPD for common aneuploidies will soon be possible. acids in maternal plasma and serum and considers two exciting recent developments that may see the routine application of NIPD for assessment of Down syndrome in the not too distant future.
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Free fetal DNA
Fetus-derived DNA is found in the plasma of all pregnant women. Furthermore, it rapidly disappears from the maternal circulation following childbirth, with the exception of one case, where there was maternal liver disease, when there were significant levels of fetal DNA remaining following parturition [2] . It is generally accepted that the source of free fetal DNA is the syncytiotrophoblast. Work in our laboratory involving the analysis of anembryonic pregnancies (which are devoid of a fetus, yet possess placental material) showed that fetus (i.e. placenta) derived DNA was found in such pregnancies in similar levels to that of age-matched controls [3] . For this reason, it is believed that the fetal fraction of free DNA in maternal plasma is derived from syncytiotrophoblasts that are undergoing apoptosis, and thus the DNA is fragmented. Studies regarding the size distribution of free fetal DNA have confirmed that it is of average size 300 bp or smaller, which is in contrast to the maternal free DNA fragments, which are considerably larger [4, 5] . The relative proportion of fetal DNA in maternal plasma is known to increase in certain pregnancy complications, including preeclampsia, and aneuploidy (review see [6, 7] ).
Efforts to increase the relative proportion of fetal DNA compared with the larger maternal fraction not only have involved size separation (on the basis of above) but also interestingly have included the use of formaldehyde as a fixative to presumably prevent the lysis of maternal cells during the isolation of the maternal plasma sample [8] . This approach was then used to quantify single nucleotide polymorphisms (SNPs) associated with the fetal DNA fraction, in order to ascertain chromosome copy number [9] . However, the formaldehyde enrichment of fetal DNA approach has not been reproducible by a number of highly competent laboratories, and recent work suggests that different regions of the fetal genome are not equally represented in the fetal DNA fraction in any case, confounding the possibility for chromosome quantitative approaches [10] .
Current diagnostic use: fetal RhD status
The molecular prenatal determination of fetal RhD blood group status was used as soon as the molecular basis of the RhD-positive/RhD-negative polymorphism was deciphered [11, 12] . This has assisted significantly in the management of hemolytic disease of the fetus and newborn (HDFN). Initially, material surplus to requirements (amniocytes) from amniotic fluid obtained for the now obsolete bilirubin Liley curve investigation was used. Because of the risk of spontaneous miscarriage, or more frequently worsening further maternal alloimmunization to the RhD antigen induced by further fetal leaks during the procedure, one of the first applications of prenatal diagnosis using free fetal DNA in maternal plasma was for RHD genotyping. The initial assays were targeted at known differences between the closely related RHD and RHCE genes and were as such relatively simplistic and technically robust. However, as the complexity of RH genetics emerged, especially the fact that multiple genetic mechanisms account for D-negative phenotypes, assays detecting both D-negative phenotypes common in Europe were developed [13] . The most widespread approach used in prenatal RHD diagnosis is to implement an assay that detects two different regions of the RHD gene, and preferably avoiding RHD exon 10, which is often detected in individuals that carry the Cde haplotype. It is strongly recommended that those considering the implementation of RHD NIPD should follow DNA extraction and PCR protocols standardized by the Special Non-Invasive Advances in Fetal and Neonatal Evaluation (SAFE) Network of Excellence, which was funded by the European commission (see www.safenoe.org) [14] .
Significant effort has been expended to detect fetal identifiers in maternal plasma samples. This is important, as it allows correct assignment of D-negative fetuses, which give no result in RHD-specific real-time PCR assays. For male fetuses, the single copy SRY gene from the Y chromosome is the best control (as it is of equivalent copy number to RHD), but an additional identifier is necessary for female fetuses. Pioneering work in the laboratory of Professor Ellen van der Schoot in the Netherlands developed the application of bi-allelic polymorphisms -genomic deletions and insertions, for use in detection of fetal DNA targets in maternal plasma [15] . However, this approach is disadvantaged by the fact that the robustness of RHD assays was often not matched for assays directed against some bi-allelic markers. Furthermore, like the allelic discrimination assay (described later), the fetus must have inherited paternal alleles not present in the maternal genome. Recent approaches have targeted hypomethylated or hypermethylated fetal DNA sequences that are epigenetically different to maternal DNA found in plasma. Initially, the Maspin gene was utilized [16] , but as detection of fetal sequences requires technically challenging bisulphite conversion techniques, a simpler method was required. By digesting DNA isolated from maternal plasma with methylationdependent restriction endonucleases, maternal (hypermethylated) DNA can be degraded, revealing only the fetal hypomethylated target following PCR. Such an example was identified by Lo et al. and involves the use of the RASSF1A locus [17] , and several others have subsequently been described [18] .
Current diagnostic use: other feto-maternal blood group incompatibility
Blood group incompatibility between fetal paternally inherited antigens other than RhD can cause HDFN. This is mainly due to anti-Rh c and E of the Rh system and anti-K of the Kell system. Diagnostic assays have been developed to detect all of these paternally inherited blood group alleles and have been described in the literature [19] .
Fetal sexing
Because it is very easy to determine the sex of a fetus by performing real-time PCR using Y chromosome specific targets, fetal sexing was one of the first clinical applications of NIPD [20] . Fetal sexing is important in cases of congenital adrenal hyperplasia (CAH) and Xlinked conditions. Routine implementation of maternal plasma based fetal sexing (normally directed toward analysis of the SRY gene and DYS14 loci of the Y chromosome) has resulted in a marked reduction in the requirement for invasive prenatal diagnosis, and should be considered in the clinical management of such cases [21] .
Shotgun sequencing: a new era in noninvasive prenatal diagnosis?
A recent paper by the group of Stephen Quake of Stanford University has provided a potentially novel approach for rapid determination of aneuploidy. The approach is to sequence a population of DNA molecules using so-called next-generation DNA sequencers. Using two such machines (a Solexa and a 454), Fan et al. [22 ] clearly demonstrate that populations of chromosome 21 and 18 derived DNAs are quantitatively different from other chromosomes in trisomy 21 and 18 maternal plasma samples, respectively. Although the paper is a preliminary report (some attention to the fact that sequences from other chromosomes have great variation in their quantity must be given), it highlights the power of sequence-specific analysis of free fetal DNA in the maternal circulation. The reason why chromosome 21 and 18 signals can be readily detected in these aneuploid fetuses is unclear, especially considering that fetal DNA fraction is a small proportion of maternal free DNA. It is, therefore, a distinct possibility that the phosphopyrolysisbased sequencing chemistry favors small DNA molecules of which the fetal DNA outnumber the maternal DNA fragments.
Free fetal RNA
It was a fundamental surprise that 'free' fetal mRNA could be found in maternal plasma samples [23] , as the RNA molecule is highly labile due to its susceptibility to nuclease attack. Subsequently, it has been postulated that the placental-expressed mRNAs are encapsulated within a syncytiotrophoblast-derived microvesicle (STBM), which may give the ''free'' fetal RNA in the maternal plasma sample such apparent RNAse resistance [24] . Nevertheless, detection of free placentally encoded mRNA in maternal blood samples has provided an ability to perform NIPD using this as source of fetal nucleic acids for diagnostic purposes.
Determination of fetal aneuploidy by allelic ratio discrimination
In 2007, Lo et al. [25 ] reported a novel approach to diagnose Down syndrome. They had previously analyzed placentally encoded transcripts found as free RNA in maternal blood and had compared them to those found in peripheral blood leukocytes. Several placental-specific transcripts were found and thus were candidate markers of the fetus in the maternal circulation. By definition of these series of fetal-specific transcripts in the maternal circulation, it is plausible that the comparative quantification of allelic SNPs arising from the same gene could be used to assess chromosome copy number. The most relevant requirement of the polymorphic SNP is that it should be carried as a single copy on the chromosome requiring quantification, thus for trisomy 21 analysis, the SNP needs to be coded by that chromosome. Of the chromosome 21 identified candidate genes, PLAC-4 was the most abundant and was later shown to be polymorphic. Furthermore, it has recently been shown that the expression of PLAC-4 is unaltered in trisomy 21 fetuses [26] .
Despite the inherent elegant design of the allelic discrimination assay, it is not technologically straightforward to implement. The assay presumes that both allelic genes will be expressed in equal amounts and that their reverse transcription and PCR amplification is perfectly symmetrical for both alleles. The chosen target allelic gene, PLAC-4, appears to meet these criteria. However, the SNPs associated with such candidate genes need to be different between mother and father to achieve allelic discrimination. When both parents are homozygous for one allelic SNP, another allele would need to be selected. The PLAC-4 gene has multiple allelic SNPs associated with it, and Sequenom have indicated in a press release (23 September 2008) that the SNPs (at least four in the PLAC-4 gene and one other undisclosed gene) they have utilized in their SEQureDx assay are sufficient for coverage of 95% of the US population. A drawback of the widespread application of this technology may be that the frequency of any given allelic SNP combination may be insufficient to provide coverage for a significant proportion of the population -for example, coverage of just 80% of the population would not be sufficient to consider routine clinical use. There have been (unpublished) reports that there are significant differences in the frequencies of the PLAC-4 alleles amongst different racial groups which indicate population-specific assays will be a requirement for such an approach to be feasible.
Conclusion
The discovery of free fetal nucleic acids (both DNA and RNA) in maternal plasma and serum have driven NIPD from a hypothetical goal in the late 1990s into a clinical reality. Since 2001, RHD genotyping has been performed using maternal plasma and has made the use of amniotic fluid obsolete for such analyses; indeed, it should be strongly discouraged. Any condition that is paternally inherited can be diagnosed using PCR-based analysis of maternal plasma or serum. The RhD-negative pregnant population (which comprises 15-18% in European and North American populations) may soon be screened to determine whether their fetus is RhD positive or not. If the fetus is defined as RhD positive, then antenatal administered prophylactic anti-D will be used. It is estimated that using such an approach, one can save up to 40% of anti-D injections, and pregnant women will avoid receiving a blood product. It should of course be stressed that this is not purely based on economics; the current production of anti-D requires the deliberate alloimmunization of male D-negative volunteers. Thus, it is not ethically sound to use a blood product derived from such donations when it is not actually needed. For NIPD to have significant impact, prenatal diagnosis of aneuploidy, and particularly trisomy 21, must be achieved. Two very recent studies have concluded that this is entirely feasible. A study has analyzed the allelic ratios associated with a placentally expressed gene for which the mRNA is found in maternal plasma. However, the frequencies of each SNP used to define the ratio must be known within the population under investigation, which is not simplistic and makes this approach rather cumbersome. Much more promising appears to be the direct assessment of fetal DNA sequences using the shotgun sequencing approach described by Fan et al., which appears to detect fetal DNA targets with relative ease and does not require any prior enrichment. With the inevitable rapid development and cost reductions associated with the new high-throughput sequencing technologies, we are quite hopeful that this approach will be at the forefront of all NIPD procedures in the near future.
